Press Releases

June 25, 2020 Cernostics Announces Blinded, Independent Validation of TissueCypher ® Performance for Predicting Risk of Progression to Esophageal Cancer in Patients with Non-Dysplastic BE

Study further validates TissueCypher® as the first and only precision medicine test proven to provide actionable data for predicting patient progression to high-grade dysplasia and esophageal adenocarcinoma Pittsburgh, Penn., June 25, 2020 – Cerno... Read more

September 10, 2020 Cernostics and Deciphex Announce Strategic Collaboration to Develop AI-Based Histology Diagnostics and Prognostics for Barrett’s Esophagus

By combining Deciphex’s unique digital pathology solutions with Cernostics tissue systems pathology approach, the partnership aims to generate novel predictive indicators using AI. PITTSBURGH and DUBLIN, September 10, 2020 (Newswire.com) –... Read more

December 3, 2013 Cernostics Raises $1.4 Million in Series B Round

Cernostics, a diagnostics company focused on delivering next generation cancer diagnostics and prognostics through a unique approach to tissue analysis, announced today that it has raised $1.4 million in Series B funding. Original investors particip... Read more

November 18, 2020 Two Independent Peer-Reviewed Studies Validate Cernostics’ TissueCypher® Barrett’s Esophagus Assay (TissueCypher®) to Accurately Predict Progression to Esophageal Cancer in Patients with Barrett’s Esophagus

SpaT Study confirms TissueCypher®’s ability to identify non-dysplastic Barrett’s Esophagus (NDBE) patients at high risk for progression to cancer who are missed by current standard of care. These “at-risk” NDBE patients progressed at a highe... Read more

January 7, 2014 Cernostics Collaborates with Prestigious Academic Medical Center in The Netherlands

Cernostics, a diagnostics company focused on delivering next generation cancer diagnostics through a unique approach to tissue analysis, announced today that it is collaborating with the Academic Medical Center in The Netherlands (AMC). As part of t... Read more

February 11, 2014 Cernostics Announces Three Patents Addressing the TissueCypher™ Technology Platform

Cernostics, a diagnostics company delivering next generation cancer diagnostics through a unique approach to tissue analysis, announced today that the United States Patent and Trademark Office has issued two patents, US Patent 8,114,615 and US Patent... Read more

October 29, 2015 Ground-breaking Cancer Diagnostic Technology Receives Phase 2 SBIR Grant

Grant will further validate Cernostics’ diagnostic technology for predicting risk of future progression to esophageal cancer in patients with Barrett’s Esophagus PITTSBURGH, PA. – The National Institutes of Health have awarded C... Read more

News